he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看编码方式地址
上一页:高血压患儿死亡简析
- 2022-05-02天使人综合征的治疗迎来新突破!FDA颁授OV101孤儿药称号
- 2022-04-27脑萎缩怎样外科手术 酒精性脑萎缩的外科手术
- 2022-04-252013年国际抗癫痫联合会抗癫痫药性使用指南
- 2022-04-132013国际抗癫痫联合会抗癫痫药用指南
- 2022-04-12【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 2022-04-11Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 2016AAN:神经专家发表了有前途的专业见解
- FDA批准Aptiom用于治疗患者癫痫发作
- 综述:癫痫持续状态诊治最新进展
- 抗癫痫药物预防新发癫痫:任重而道远
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 女性癫痫的治疗多少钱
- 治疗脑炎后遗症的方法有哪些?
- 心理百科:春节期间小心疾病
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- 月经性癫痫患者妊娠期癫痫控制更好
- 羊角病能生孩子吗?
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- 成人羊角风病的病因是什么?
- 癫痫定位新方法:无框架立体定向脑电图技术
- 月经期间要注意 有些药物和食物不能食用
- 癫痫猝死:凶手是谁?
- 癫痫治疗障碍仍难以克服
- 黑芝麻的营养价值 吃黑芝麻的好处
- 三庚酸酯可治疗1型转运体缺陷综合征
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 2015第31届国际癫痫大会(IEC)
- 北京癫痫手术费用
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 沈阳癫痫病医院治疗额度是多少
- 热性癫痫处理指南解读
- 晚期小儿癫痫病有什么症状
- 脑电图为什么要除此以外复查
- 癫痫病吃什么可以操纵
- 晚期癫痫病症状表现是什么
- 导致癫痫病的致病都有什么
- 一种特异性的癫痫发作类型【音频】
- 癫痫病的疗程费用
- 戴只运动鞋就能测癫痫发作?智能穿戴设备太牛了
- 最佳癫痫病治疗方法副作用是什么
- 38年病史的癫痫患者一封感谢信 说出浓浓医患情
- 怎样放射治疗癫痫病最有效